Always eager to take on an opportunity to serve the public good, he was also on the programming committee for the continuing ...

In animal models, NU-9 was found to show promise in treating Alzheimer's by reducing toxic protein buildup and brain ...

Schoox, a global leader in frontline workforce learning and skills development, has been selected by the ALS Association to ...

NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new ...

A rare mutation that leads to high CREB3 activity is associated with a reduced risk of developing ALS and slower disease ...

Ractigen Therapeutics, a clinical-stage biopharmaceutical company focused on developing pioneering RNA-based medicines, today announced that the final, positive results from the Investigator-Initiated ...

Neuroimmunologist Norbert Žilka from the Institute of Neuroimmunology of the Slovak Academy of Sciences became involved in ...

Amylyx (AMLX) announced that the first participant has been dosed in LUMINA, the company’s Phase 1, multinational, randomized, double-blind, ...

Garmin today announced the Variatm Vue headlight camera, the latest addition to its lineup of accessories designed to help ...

Discover six life-changing books that offer unexpected insights. These titles delve into themes of personal growth, ...

The results of a phase-2a clinical trial of IPL344 were published in Muscle and Nerve, the leading American scientific journal specializing in ALS and neuromuscular diseases.

The Ohio House Insurance Committee will hear proponent testimony on HB 24, a bill that would expand Medigap coverage to patients under 65, on Tuesday afternoon.